CDXI (CDXI) Stock Price & Analysis
CDXI (CDXI) rose 0.00% to USD 0 as of June 10, 2026 at 04:03 UTC, according to Nexqual real-time market data.
CDXI last closed at USD 0; the session ranged USD 0–0 on volume of 1 shares. Market capitalization is $80, with a 52-week range of USD 0–0 (PNK). Source: Nexqual, June 10, 2026 at 04:03 UTC.
Key Statistics (as of June 10, 2026 at 04:03 UTC)
| Price | USD 0 |
|---|---|
| Change | ▲ 0.00% (up) |
| Previous Close | USD 0 |
| Open | USD 0 |
| Day Range | USD 0 – 0 |
| 52-Week Range | USD 0 – 0 |
| Volume | 1 shares |
| Market Cap | $80 |
| Exchange | PNK |
Technical Analysis (CDXI)
Nexqual's technical model rates CDXI "STRONG SELL" based on 0 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 04:03 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 100 (overbought) |
| vs SMA50 | Below (USD 0) |
| MACD | 0 (negative) |
Analyst Ratings (CDXI)
Wall Street analysts rate CDXI "None", per Nexqual as of June 10, 2026 at 04:03 UTC.
| Consensus Rating | None |
|---|
Earnings (CDXI)
Source: Nexqual, June 10, 2026 at 04:03 UTC.
Financials & Fundamentals (CDXI)
| Total Revenue | $500,707 |
|---|---|
| Revenue Growth (YoY) | -26.80% |
| Gross Margin | +65.75% |
| Operating Margin | -737.58% |
| Profit Margin | +0.00% |
| Current Ratio | 0.09 |
| Total Cash | $61,713 |
| Total Debt | $5.40M |
| Free Cash Flow | $349,138 |
Source: Nexqual, June 10, 2026 at 04:03 UTC.
Financial Health Score (CDXI)
Nexqual rates CDXI's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 04:03 UTC.
| Growth | Critical — Revenue -27% YoY (latest Q), sharp decline |
|---|---|
| Profitability | Critical — Heavily loss-making — early-stage company |
| Balance Sheet | Mixed — $62K cash vs $5M debt |
| Cash Flow | Strong — FCF $349K, 70% margin |
| Efficiency | Mixed — No data |
Ownership (CDXI)
| Insider Ownership | +0.00% |
|---|---|
| Institutional Ownership | +0.00% |
| Shares Outstanding | 802,516 |
| Float | 590,202 |
Source: Nexqual, June 10, 2026 at 04:03 UTC.
Leadership (CDXI)
CDXI is led by David G. Watumull (age 75), Chairman & CEO, per Nexqual as of June 10, 2026 at 04:03 UTC.
| Chairman & CEO | David G. Watumull (age 75) |
|---|---|
| COO & CFO | David M. Watumull (age 43) |
| Vice President of Retail Sales & Marketing | Gilbert Shin |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| CLCS | Cell Source, Inc. | USD 0.82 | ▲ 0% |
| CRVW | Careview Communications, Inc. | USD 0.05 | ▲ 9.8% |
| FPMI | FLUOROPHARMA MEDICAL INC | USD 0 | ▲ 0% |
| BNKL | BIONIK LABORATORIES CORP | USD 0 | ▲ 0% |
| BICX | BioCorRx Inc. | USD 0.4 | ▲ 5.82% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 04:03 UTC. This page is informational and not investment advice.